glofitamab-gxbm

{
  "id": "MLC-T-ONC-013969",
  "term": "glofitamab-gxbm",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab-gxbm binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.",
  "synonyms": [
    "anti-CD20/CD3 bispecific monoclonal antibody RO7082859",
    "anti-CD20 x anti-CD3 bispecific monoclonal antibody RO7082859",
    "glofitamab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/glofitamab-gxbm/"
}